Genetic products differentially expressed in tumors and the use thereof
AssigneeGanymed Pharmaceuticals AG
InventorsUgur Sahin, Özlem Türeci, Michael Koslowski
Life of this patent
Estimating the term…
Abstract
The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.
Claims28
1-98. (canceled)
A pharmaceutical composition, comprising an agent which inhibits or suppresses expression or biological activity of a tumor-associated antigen, said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting essentially of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting essentially of SEQ ID NOs:
- 7-8, 117, 119, and a part or derivative thereof;
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions;
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b);
- and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
A pharmaceutical composition, comprising a tumor-inhibiting agent, which is selective for cells expressing or abnormally expressing a tumor-associated antigen, said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting essentially of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting essentially of SEQ ID NOs:
- 7-8, 117, 119, and a part or derivative thereof;
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions;
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b);
- and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
An agent, which binds specifically to a protein or polypeptide or to a part thereof, said protein or polypeptide being encoded by a nucleic acid selected from the group consisting essentially of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting essentially of SEQ ID NOs:
- 7-8, 117, 119, and a part or derivative thereof;
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions;
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b);
- and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
A method of treating a disease characterized by expression or abnormal expression of a tumor-associated antigen, comprising:
- administering a pharmaceutical composition including an agent that is capable of selectively binding to cells expressing or abnormally expressing a tumor-associated antigen, said tumor-associated antigen having a sequence encoded by a nucleic acid which is selected from the group consisting essentially of:
- (a) a nucleic acid which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:
- 7-8, 117, 119, and a part or derivative thereof;
- (b) a nucleic acid which hybridizes with the nucleic acid of (a) under stringent conditions;
- (c) a nucleic acid which is degenerate with respect to the nucleic acid of (a) or (b);
- and
- (d) a nucleic acid which is complementary to the nucleic acid of (a), (b) or (c).
Dependencies are inferred from the claim text.